Publications

Siolta Therapeutics Initiates Collaboration with Bio-Me to Develop Microbiome-based Prognostics for Early Identification of Allergy and Asthma

Siolta Therapeutics Closes $30M Series B Financing to Support Clinical Development of Lead Program

FDA Grants Fast Track Status to STMC-103H Program for Allergic Disease Prevention

Dr. John Martin, Former CEO/Chairperson of Gilead, Joins Siolta Therapeutics Executive Advisory Team

Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance

Siolta Therapeutics Supports the 3rd Annual Biotech Week at SFUSD